REFERENCES
1. Clark CM, Karlawish JHT. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003;138:400-10.
4. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011;1:a006189.
5. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.
6. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age, sex, and APOE ε4 effects on memory, brain structure, and β-amyloid across the adult life span. JAMA Neurol 2015;72:511-9.
7. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010;67:353-64.
8. Rodrigue KM, Kennedy KM, Park DC. Beta-amyloid deposition and the aging brain. Neuropsychol Rev 2009;19:436-50.
9. Oh H, Mormino EC, Madison C, Hayenga A, Smiljic A, Jagust WJ. β-amyloid affects frontal and posterior brain networks in normal aging. Neuroimage 2011;54:1887-95.
10. Bourgeat P, Chételat G, Villemagne VL, et al. AIBL Research Group. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010;74:121-7.
11. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-83.
12. Petersen RC, Aisen P, Boeve BF, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013;74:199-208.
13. Erten-Lyons D, Woltjer RL, Dodge H, et al. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 2009;72:354-60.
14. Lesné SE, Sherman MA, Grant M, et al. Brain amyloid-β oligomers in ageing and Alzheimer’s disease. Brain 2013;136:1383-98.
15. Bischof GN, Rodrigue KM, Kennedy KM, Devous MD Sr, Park DC. Amyloid deposition in younger adults is linked to episodic memory performance. Neurology 2016;87:2562-6.
16. Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of amyloid and tau with cognition in preclinical alzheimer disease: a longitudinal study. JAMA Neurol 2019;76:915-24.
17. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 2013;74:905-13.
18. Drummond E, Wisniewski T. Alzheimer’s disease: experimental models and reality. Acta Neuropathol 2017;133:155-75.
19. Kitazawa M, Medeiros R, Laferla FM. Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des 2012;18:1131-47.
20. Cummings BJ, Head E, Ruehl W, Milgram NW, Cotman CW. The canine as an animal model of human aging and dementia. Neurobiology of Aging 1996;17:259-68.
21. Head E, McCleary R, Hahn FF, Milgram NW, Cotman CW. Region-specific age at onset of β-amyloid in dogs. Neurobiol Aging 2000;21:89-96.
22. Pugliese M, Gangitano C, Ceccariglia S, et al. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes. Brain Res 2007;1139:85-94.
23. Head E, Pop V, Sarsoza F, et al. Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J Alzheimers Dis 2010;20:637-46.
24. Youssef SA, Capucchio MT, Rofina JE, et al. Pathology of the aging brain in domestic and laboratory animals, and animal models of human neurodegenerative diseases. Vet Pathol 2016;53:327-48.
25. Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW. Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem 1996;66:11-23.
26. Adams B, Chan A, Callahan H, Milgram NW. The canine as a model of human cognitive aging: recent developments. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:675-92.
27. Head E. A canine model of human aging and Alzheimer’s disease. Biochim Biophys Acta 2013;1832:1384-9.
28. Rofina JE, van Ederen AM, Toussaint MJ, et al. Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer’s disease. Brain Res 2006;1069:216-26.
29. Chow VW, Mattson MP, Wong PC, Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med 2010;12:1-12.
30. Yu CH, Song GS, Yhee JY, et al. Histopathological and immunohistochemical comparison of the brain of human patients with Alzheimer’s disease and the brain of aged dogs with cognitive dysfunction. J Comp Pathol 2011;145:45-58.
31. Broersen K, Rousseau F, Schymkowitz J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer’s disease: oligomer size or conformation? Alzheimers Res Ther 2010;2:12.
32. Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics. Alzheimers Res Ther 2014;6:42.
33. Morgado I, Fändrich M. Assembly of Alzheimer’s Aβ peptide into nanostructured amyloid fibrils. Current opinion in colloid & interface science 2011;16:508-14.
34. Sengupta U, Nilson AN, Kayed R. The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 2016;6:42-9.
36. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-9.
37. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-12.
38. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 2012;15:349-57.
39. Zhao LN, Long HW, Mu Y, Chew LY. The toxicity of amyloid β oligomers. International journal of molecular sciences 2012;13:7303-27.
40. Abey A, Davies D, Goldsbury C, Buckland M, Valenzuela M, Duncan T. Distribution of tau hyperphosphorylation in canine dementia resembles early Alzheimer’s disease and other tauopathies. Brain Pathol 2021;31:144-62.
41. Papaioannou N, Tooten PC, van Ederen AM, et al. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid 2001;8:11-21.
42. Pugliese M, Mascort J, Mahy N, Ferrer I. Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits. Acta Neuropathol 2006;112:175-83.
43. Schmidt F, Boltze J, Jäger C, et al. Detection and quantification of β-amyloid, pyroglutamyl Aβ, and tau in aged canines. J Neuropathol Exp Neurol 2015;74:912-23.
44. Wegiel J, Wisniewski HM, Sołtysiak Z. Region- and cell-type-specific pattern of tau phosphorylation in dog brain. Brain Research 1998;802:259-66.
45. Armstrong RA. Alzheimer’s disease and the eye. Journal of Optometry 2009;2:103-11. Available from:
46. Santos CY, Johnson LN, Sinoff SE, Festa EK, Heindel WC, Snyder PJ. Change in retinal structural anatomy during the preclinical stage of Alzheimer’s disease. Alzheimers Dement (Amst) 2018;10:196-209.
47. Marquié M, Castilla-Martí M, Valero S, et al. Visual impairment in aging and cognitive decline: experience in a Memory Clinic. Sci Rep 2019;9:8698.
48. Lee ATC, Richards M, Chan WC, Chiu HFK, Lee RSY, Lam LCW. Higher dementia incidence in older adults with poor visual acuity. J Gerontol A Biol Sci Med Sci 2020;75:2162-8.
49. Habiba U, Merlin S, Lim JKH, et al. Age-specific retinal and cerebral immunodetection of amyloid-β plaques and oligomers in a rodent model of Alzheimer’s disease. J Alzheimers Dis 2020;76:1135-50.
50. Lee S, Jiang K, McIlmoyle B, et al. Amyloid Beta immunoreactivity in the retinal ganglion cell layer of the Alzheimer’s eye. Front Neurosci 2020;14:758.
51. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2011;54 Suppl 1:S204-17.
52. Tsai Y, Lu B, Ljubimov AV, et al. Ocular changes in TgF344-AD rat model of Alzheimer’s disease. Invest Ophthalmol Vis Sci 2014;55:523-34.
53. Jentsch S, Schweitzer D, Schmidtke KU, et al. Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer’s disease. Acta Ophthalmol 2015;93:e241-7.
54. den Haan J, Morrema THJ, Verbraak FD, et al. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas. Acta Neuropathol Commun 2018;6:147.
55. Habiba U, Descallar J, Kreilaus F, et al. Detection of retinal and blood Aβ oligomers with nanobodies. Alzheimers Dement (Amst) 2021;13:e12193.
56. Yi J, Chen B, Yao X, Lei Y, Ou F, Huang F. Upregulation of the lncRNA MEG3 improves cognitive impairment, alleviates neuronal damage, and inhibits activation of astrocytes in hippocampus tissues in Alzheimer’s disease through inactivating the PI3K/Akt signaling pathway. J Cell Biochem 2019;120:18053-65.
57. David MA, Jones DR, Tayebi M. Potential candidate camelid antibodies for the treatment of protein-misfolding diseases. J Neuroimmunol 2014;272:76-85.
58. van Eersel J, Stevens CH, Przybyla M, et al. Early-onset axonal pathology in a novel P301S-Tau transgenic mouse model of frontotemporal lobar degeneration. Neuropathol Appl Neurobiol 2015;41:906-25.
59. Radde R, Bolmont T, Kaeser SA, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006;7:940-6.
60. Nakayama H, Uchida K, Doi K. A comparative study of age-related brain pathology - are neurodegenerative diseases present in nonhuman animals ? Med Hypotheses 2004;63:198-202.
61. Cummings BJ, Pike CJ, Shankle R, Cotman CW. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer’s disease. Neurobiology of Aging 1996;17:921-33.
62. Breydo L, Uversky VN. Structural, morphological, and functional diversity of amyloid oligomers. FEBS Lett 2015;589:2640-8.
63. Silva EG, Dubielzig R, Zarfoss MK, Anibal A. Distinctive histopathologic features of canine optic nerve hypoplasia and aplasia: a retrospective review of 13 cases. Vet Ophthalmol 2008;11:23-9.
64. Rüttimann G, Daicker B. Complex colobomas in the anterior eye segment in a beagle hound. Zentralbl Veterinarmed A 1982;29:528-37.
66. Casaletto KB, Ward ME, Baker NS, et al. Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults. Neurobiol Aging 2017;51:141-7.
67. Alonso-Caneiro D, Read SA, Collins MJ. Automatic segmentation of choroidal thickness in optical coherence tomography. Biomed Opt Express 2013;4:2795-812.
68. Ko F, Muthy ZA, Gallacher J, et al. UK Biobank Eye & Vision Consortium. Association of retinal nerve fiber layer thinning with current and future cognitive decline: a study using optical coherence tomography. JAMA Neurol 2018;75:1198-205.
69. Schütt T, Helboe L, Pedersen LØ, Waldemar G, Berendt M, Pedersen JT. Dogs with cognitive dysfunction as a spontaneous model for early Alzheimer’s disease: a translational study of neuropathological and inflammatory markers. J Alzheimers Dis 2016;52:433-49.
70. Stylianaki I, Polizopoulou ZS, Theodoridis A, Koutouzidou G, Baka R, Papaioannou NG. Amyloid-beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome. J Vet Intern Med 2020;34:1532-40.
71. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. Water-soluble abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996;271:4077-81.
72. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95:6448-53.
73. Cizas P, Budvytyte R, Morkuniene R, et al. Size-dependent neurotoxicity of beta-amyloid oligomers. Arch Biochem Biophys 2010;496:84-92.
74. Rusbridge C, Salguero FJ, David MA, et al. An aged canid with behavioral deficits exhibits blood and cerebrospinal fluid amyloid beta oligomers. Front Aging Neurosci 2018;10:7.
75. Naaman E, Ya’ari S, Itzkovich C, et al. The retinal toxicity profile towards assemblies of Amyloid-β indicate the predominant pathophysiological activity of oligomeric species. Sci Rep 2020;10:20954.
76. American Kennel Club. Dog years to human years 2018, January 02. Available from: https://www.akcpetinsurance.com/blog/year-of-the-dog [Last accessed on 23 May 2022].
77. Ozawa M, Chambers JK, Uchida K, Nakayama H. The relation between canine cognitive dysfunction and age-related brain lesions. J Vet Med Sci 2016;78:997-1006.
78. Kiatipattanasakul W, Nakamura S, Hossain MM, et al. Apoptosis in the aged dog brain. Acta Neuropathol 1996;92:242-8.
79. Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight 2017;2:93621.
80. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J 2006;20:419-25.
81. El-agnaf OM, Walsh DM, Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. The Lancet Neurology 2003;2:461-2.
82. Mucke L, Selkoe DJ. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012;2:a006338.
83. Kim HJ, Chae SC, Lee DK, et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 2003;17:118-20.
85. Lynn SA, Johnston DA, Scott JA, et al. Oligomeric Aβ1-42 induces an AMD-like phenotype and accumulates in lysosomes to impair RPE function. Cells 2021;10:413.
86. Ratnayaka JA, Serpell LC, Lotery AJ. Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye (Lond) 2015;29:1013-26.
87. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 2006;116:378-85.
88. Denenberg S, Liebel F, Rose J. Behavioural and medical differentials of cognitive decline and dementia in dogs and cats. In: Landsberg G, Maďari A, Žilka N, editors. Canine and feline dementia. Cham: Springer International Publishing; 2017. p. 13-58.
89. Acland G, Aguirre G. Retinal degenerations in the dog: IV. Early retinal degeneration (erd) in Norwegian elkhounds. Exp Eye Res 1987;44:491-521.
90. Ozawa M, Inoue M, Uchida K, Chambers JK, Takeuch Y, Nakayama H. Physical signs of canine cognitive dysfunction. J Vet Med Sci 2019;81:1829-34.
91. Weber SA, Patel RK, Lutsep HL. Cerebral amyloid angiopathy: diagnosis and potential therapies. Expert Rev Neurother 2018;18:503-13.
92. Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J Anat 2005;206:319-48.
93. Shi H, Koronyo Y, Rentsendorj A, et al. Identification of early pericyte loss and vascular amyloidosis in Alzheimer’s disease retina. Acta Neuropathol 2020;139:813-36.
94. Sharafi SM, Sylvestre JP, Chevrefils C, et al. Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. Alzheimers Dement (N Y) 2019;5:610-7.
95. Arnsten AFT, Datta D, Del Tredici K, Braak H. Hypothesis: tau pathology is an initiating factor in sporadic Alzheimer’s disease. Alzheimers Dement 2021;17:115-24.
96. Bilousova T, Miller CA, Poon WW, et al. Synaptic amyloid-β oligomers precede p-Tau and differentiate high pathology control cases. Am J Pathol 2016;186:185-98.
97. Schön C, Hoffmann NA, Ochs SM, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One 2012;7:e53547.
98. Rofina J, van Andel I, van Ederen AM, Papaioannou N, Yamaguchi H, Gruys E. Canine counterpart of senile dementia of the Alzheimer type: amyloid plaques near capillaries but lack of spatial relationship with activated microglia and macrophages. Amyloid 2003;10:86-96.
99. Colle MA, Hauw JJ, Crespeau F, et al. Vascular and parenchymal abeta deposition in the aging dog: correlation with behavior. Neurobiol Aging 2000;21:695-704.
100. De Felice FG, Wu D, Lambert MP, et al. Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 2008;29:1334-47.
101. Manczak M, Reddy PH. Abnormal interaction of oligomeric amyloid-β with phosphorylated tau: implications to synaptic dysfunction and neuronal damage. J Alzheimers Dis 2013;36:285-95.
102. Fein JA, Sokolow S, Miller CA, et al. Co-localization of amyloid beta and tau pathology in Alzheimer’s disease synaptosomes. Am J Pathol 2008;172:1683-92.
103. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK. Co-occurrence of Alzheimer’s disease β-amyloid and τ pathologies at synapses. Neurobiol Aging 2010;31:1145-52.
104. Lockhart SN, Schöll M, Baker SL, et al. Amyloid and tau PET demonstrate region-specific associations in normal older people. Neuroimage 2017;150:191-9.
105. Golde TE, Schneider LS, Koo EH. Anti-aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift. Neuron 2011;69:203-13.
106. Parker HG, Kim LV, Sutter NB, et al. Genetic structure of the purebred domestic dog. Science 2004;304:1160-4.
107. Davis PR, Head E. Prevention approaches in a preclinical canine model of Alzheimer’s disease: benefits and challenges. Front Pharmacol 2014;5:47.
108. Awano T, Johnson GS, Wade CM, et al. Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2009;106:2794-9.
